15
Participants
Start Date
July 3, 2023
Primary Completion Date
April 13, 2027
Study Completion Date
April 13, 2027
Inebilizumab
Inebilizumab administered intravenously (IV) over a total of 28 weeks.
RECRUITING
Clinic for Neurology and Psychiatry for Children and Youth, Belgrade
RECRUITING
Karolinska Universitetssjukhuset Solna, Stockholm
RECRUITING
Loma Linda University Children's Hospital - PIN, Loma Linda
RECRUITING
Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-Bicêtre
RECRUITING
UCSD Altman Clinical and Translational Research Institute Building, La Jolla
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Hospital de Pediatría S.A.M.I.C.- Prof. Dr. Juan P. Garrahan, Parque Patricios
RECRUITING
Hospital Santa Izabel-Rua Floriano Peixoto 300, Salvador
RECRUITING
Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS), Porto Alegre/RS
RECRUITING
CPQuali Pesquisa Clínica Sao Paulo, São Paulo
RECRUITING
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo
RECRUITING
Hospital For Sick Children, Toronto
RECRUITING
Erasmus MC Sophia Children's Hospital-Wytemaweg 80, Rotterdam
RECRUITING
Uniwersyteckie Centrum Kliniczne w Gdansku - Smoluchowskiego 17, Gdansk
RECRUITING
Hospital Sant Joan de Deu - PIN, Espluges de Llobregat
RECRUITING
Evelina London Children's Hospital, London
RECRUITING
Great Ormond Street Hospital - PPDS, London
RECRUITING
Birmingham Women's and Children's NHS Foundation Trust, Birmingham
Lead Sponsor
Amgen
INDUSTRY